

Docket No. 258739US0PCT

DEC 03 2004

! DT03 Rec'd PCT/PTO 03 DEC 2004  
PCT #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Masaaki NAGASAWA, et al.

SERIAL NO: 10/507,361

GAU:

FILED: September 20, 2004

EXAMINER:

FOR: 1-N-AMINOBENZIMIDAZOLE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Surinder Sachar

Norman F. Oblon  
Registration No. 24,619

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar  
Registration No. 34,423

Form PTO 1449 (Modified)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 258739US0PCT		SERIAL NO. 10/507,361	
LIST OF REFERENCES CITED BY APPLICANT			APPLICANT Masaaki NAGASAWA, et al.					
			FILING DATE September 20, 2004			GROUP		
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AA	2003/0236411	12/25/03	NAGASAWA, Masaaki et al. (US Serial No. 10/380,158)				
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
	AB	54-141783 -	11/05/79	JP (with English abstract)	YES		NO	
	AC	94 27988 -	12/08/94	WO			NO	
	AD	61-50978 -	03/13/86	JP (with English abstract)			NO	
	AE	64-6270 -	01/10/89	JP (with English abstract)			NO	
	AF	61-22079 -	01/30/86	JP (with English abstract)			NO	
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>								
	AG	ANDO, Takashi et al. "1. Study of the Treatment of Gastric Ulcer Considering the Characteristics of Genetic Polymorphism of the Metabolic Enzyme CYP2C19", Gastric Secretion Research, vol. 34, pages 39-40, with full English translation 2002						
	AH	SHIMATANI, Tomohiko et al. "1. Are Proton Pump Inhibitors the Most Potent Gastric Acid Secretion Inhibitors?", Gastric Secretion Research, vol. 34, pages 99-103, with full English translation 2002						
	AI	KODAIRA, Junichi et al. "2. Relation between Acid Secretion Inhibition Effect of PPIs and CYP2C19 Genetic Polymorphisms in H. pylori-Negative Healthy Volunteers", Gastric Secretion Research, vol. 34, pages 105-108, with full English translation 2002						
	AJ	SAITO, Hisato et al. "3. Acid Secretion Inhibition Effect of PPI at an Initial Stage of Administration (in the Case of CYP2C19EM)", Gastric Secretion Research, vol. 34, pages 109-112, with full English translation 2002						
	AK	ISHIZAKI, Takashi. "What do the Latest Findings in Clinical Pharmacology Say about Choosing the Right PPI?", Nikkei Medical, vol. 7, pages 174-175, with full English translation 2001						
	AL	ANDERSSON, Tommy. "Pharmacokinetics, Metabolism and Interaction of Acid Pump Inhibitors", Clin. Pharmacokinet, vol. 31, no. 1, pages 9-28 1996						
	AM	HORAI, Y. et al. "Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes", Aliment. Pharmacol. Ther., vol. 15, pages 793-803 2001						
	AN	KRUSEKOPF, S. et al. "Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line", Xenobiotica, vol. 27, no. 1, pages 1-9 1997						
	AO	FURUTA, Takahisa et al. "Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer", Annals of Internal Medicine, vol. 129, no. 12, pages 1027-1030 1998						
	AP	FURUTA, Takahisa et al. "Effect of Genotypic Differences in CYP2C19 Status on the Cure Rates for Gastroesophageal Reflux Disease by Lansoprazole", Gastroenterology, vol. 120, suppl. 1, page A-432, #2203 2001						
	AQ	PARK, Soo-Heon et al. "Effect of CYP2C19 Polymorphism on Rabeprazole Induced Nocturnal Acid Breakthrough", Gastroenterology, vol. 120, suppl. 1, page A-435, #2219 2001						
	AR	SAGAR, M. et al. "Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment", Aliment. Pharmacol. Ther., vol. 13, pages 453-458 1999						
	AS	KOKUFU, T. et al. "Effects of Lansoprazole on pharmacokinetics and metabolism of theophylline", Eur. J. Clin. Pharmacol., vol. 48, pages 391-395 1995						
	AT	DIAZ, Dominique et al. "Omeprazole Is an Aryl Hydrocarbon-like Inducer of Human Hepatic Cytochrome P450", Gastroenterology, vol. 99, pages 737-747 1990						
Examiner					Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

U.S. PCT Application Serial No.: 10/507,361  
Docket No.: 258739US0PCT

#### STATEMENT OF RELEVANCY

- 1) References \_\_\_\_\_ have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References \_\_\_\_\_ have been cited in the corresponding \_\_\_\_\_ Search Report. A copy of these references is being submitted herewith.
- 3) References AB-AT are discussed in the specification. A copy of these references is being submitted here with.
- 4) References \_\_\_\_\_ are additional prior art known to Applicant. A copy of these references is being submitted herewith.

**LIST OF RELATED CASES**

<u>Docket Number</u>	<u>Serial or Patent Number</u>	<u>Filing or Issue Date</u>	<u>Patent Appl. Publication No.</u>	<u>Inventor/Applicant</u>
258739US0PCT*	10/507,361	09/20/04		NAGASAWA, et al.
235424US0PCT	10/380,158	03/17/04	US 2003-0236411 A1	NAGASAWA, et al.

\*Present Application; listed for information  
NFO/hah/get